Frequently Asked Questions
The market is segmented based on , By Type (Agoraphobia, Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Specific Phobias, Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD)), Therapy and Devices (Electroconvulsive Therapy ECT, Cognitive-Behavioral Therapy (CBT)), Drug Class (Benzodiazepines (BZD), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Monoamine Oxidase Inhibitors (MAOIs), Anti-Depressants, Tricyclic Antidepressants (TCAs), Pregabalin, Buspirone, Sertraline), Distribution Channel (Pharmacies, Drug Stores, E-Commerce, Online, Offline), (Administration Oral, Parenteral, Others), Treatment (Medication, Beta Blockers, Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Benzodiazepines, Anti-epilepsy, Others), Dosage (Tablets, Injections, Others), End-User (Hospitals, Mental Healthcare Centres, Asylums, Others) – Industry Trends and Forecast to 2030.
.
The Global Panic Disorders Market size was valued at USD 9.58 USD Billion in 2022.
The Global Panic Disorders Market is projected to grow at a CAGR of 4.06% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America..
